ORPHA:91355
Sheehan syndrome
Publications
1,471
Trials
0
Interventional, condition-specific
Researchers
794
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
Sheehan syndrome is a rare, acquired, pituitary hormone deficiency disorder resulting from pituitary necrosis following peri- or postpartum hemorrhage characterized by various symptoms depending on resulting hormone decrease (e.g. failure or difficulty with lactation, oligo- or amenorrhea, hot flashes, decreased libido, weakness, fatigue, anorexia, nausea, vomiting, , hyponatremia, dizziness, decreased muscle mass, adrenal crisis). Secondary hypothyroidism and secondary adrenal insufficiency may also be presenting signs.
How rare: How common this is has not been clearly measured.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0019618
- UMLS:C0242342
- NCIT:C35300
Additional Mondo synonyms (2)
Sheehan's syndrome · postpartum hypopituitarism
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
Research-stage checklist from open sources (GenCC, literature, Monarch when enriched, ClinicalTrials.gov). Not a prognosis or care recommendation.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
1,471 matched papers (478 in last 10 years) Source
- Phenotype characterisedPresent
49 HPO annotations (e.g. Sensorineural hearing impairment; Diplopia; Hashimoto thyroiditis) Source
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialNot found
No matched interventional trial under our ClinicalTrials.gov rules
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
49
Associated phenotypes · MONDO:0019618
- Sensorineural hearing impairment
- Diplopia
- Hashimoto thyroiditis
- Antinuclear antibody positivity
- Poor appetite
Showing 5 of 49 — open Monarch for the full list.
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
1,471
1,471 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
1,471 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
478 in the last 10 years · low confidence
Phrase hits: 1,471 · MeSH hits: 0
Who's working on it?
794
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Laway BA14 papers · 2026
Department of Endocrinology, Sher-I-Kashmir Institute of Medical Sciences, Srinagar, Kashmir, India.
Papers in Europe PMC - 02mir sa7 papers · 2025
Division of Internal Medicine and Endocrinology, Government Medical College, Srinagar, Jammu and Kashmir, India.
Papers in Europe PMC - 03Baba MS6 papers · 2025
Department of Endocrinology, Sher-I-Kashmir Institute of Medical Sciences, Srinagar, Kashmir, India.
Papers in Europe PMC - 04Dutta P6 papers · 2026
Department of Endocrinology, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh 160012, India.
Papers in Europe PMC - 05singh h6 papers · 2025
Division of Internal Medicine and Endocrinology, Government Medical College, Srinagar, Jammu and Kashmir, India.
Papers in Europe PMC - 06Wang Y5 papers · 2025
Department of Oncology Hebei Chest Hospital Shijiazhuang China.
Papers in Europe PMC - 07Bhat JA4 papers · 2025
Department of Internal Medicine and Endocrinology, Government Medical College, Srinagar, Jammu and Kashmir, India.
Papers in Europe PMC - 08Bhat MH4 papers · 2025
Department of Internal Medicine and Endocrinology, Government Medical College, Srinagar, Jammu and Kashmir, India.
Papers in Europe PMC - 09Das L4 papers · 2026
Department of Endocrinology, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh 160012, India.
Papers in Europe PMC - 10Ghosh S4 papers · 2022
Department of Endocrinology, Institute of Post Graduate Medical Education & Research, Kolkata, India. Electronic address: drsujoyghosh2000@gmail.com.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).
Data as of 11 September 2026 · last trial check 11 September 2026
No matched interventional trials. This is true for 77.2% of diseases in the trials denominator (5501 of 7126). Here are the researchers publishing on it.
low confidence · 38.6th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 11 · after dedupe 11 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 11 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (11)
- isrctn·ISRCTN42784463·No longer recruiting·Treatment of chronic fatigue by transcranial direct current stimulation (tDCS)
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN73588250·No longer recruiting·The purpose of the trial is to test the safety, tolerability and efficacy of the drug tildacerfont, that is being developed for the treatment of major depressive disorder
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN83479057·Recruiting·A clinical study to investigate whether third-line treatments work better as a second-line treatment for people diagnosed with schizophrenia
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN31103960·No longer recruiting·A dose-finding and proof-of-concept study of the efficacy and safety of MSP-1014.OX in patients with major depressive disorder
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN19930942·No longer recruiting·A single-dose study of zavegepant in healthy male volunteers
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN36202964·No longer recruiting·Clinical study to assess the efficacy and safety of Silexan in patients with depression
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN83227991·No longer recruiting·Clinical trial to explore treatment effects of Ginkgo biloba Extract EGb 761® in patients with different types of vertigo and effect modification by type of vertigo, chronicity and concomitant pathologies
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN02262139·No longer recruiting·To compare the efficacy and safety of Ginkgo biloba extract EGb 761® and betahistine in the treatment of vertigo
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN74919979·No longer recruiting·Information technology in mental health
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN81773762·No longer recruiting·A randomised controlled trial to compare normoxic versus standard cardiopulmonary bypass in cyanotic children undergoing cardiac surgery
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN05610852·No longer recruiting·Comparison of BAHA Softband vs conventional hearing aid in management of hearing loss in young children with Down's syndrome
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Sheehan syndrome — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Sheehan syndrome" OR "Sheehan's syndrome" OR "postpartum hypopituitarism"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Sheehan syndrome" OR "Sheehan's syndrome" OR "postpartum hypopituitarism"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is short or not clearly distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
- Publication count (1471) is extremely high with unknown/missing prevalence — treat as possible over-matching, not proven research intensity
Ingested 2026-07-27T03:59:26.709Z
